Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gerard Sanacora

Showing results (1-10 of 195) with videos related to

Pageof 20
Sort By:
The American Journal of Psychiatry|March 2, 2019
Caution Against Overinterpreting Opiate Receptor Stimulation as Mediating Antidepressant Effects of KetamineGerard Sanacora
The Journal of Clinical Psychiatry|December 25, 2009
Do glutamatergic agents represent a new class of antidepressant drugs? Part 2Gerard Sanacora
Biological Psychiatry|February 18, 2010
Cortical inhibition, gamma-aminobutyric acid, and major depression: there is plenty of smoke but is there fire?Gerard Sanacora
The Journal of Clinical Psychiatry|February 19, 2009
Reviewing medications for bipolar disorder: understanding the mechanisms of actionGerard Sanacora
JAMA Psychiatry|July 13, 2017
Ketamine for the Treatment of Depression-ReplyGerard Sanacora
The Journal of Clinical Psychiatry|March 7, 2009
New understanding of mechanisms of action of bipolar medicationsGerard Sanacora
The Journal of Clinical Psychiatry|November 13, 2009
Do glutamatergic agents represent a new class of antidepressant drugs? Part 1Gerard Sanacora
Biological Psychiatry|June 23, 2018
Hopes and Skepticism for Unraveling the Unique Mechanisms of Ketamine's Rapid Onset Antidepressant Actions in Rodent ModelsGerard Sanacora
JAMA Psychiatry|June 16, 2016
What Are We Learning From Early-Phase Clinical Trials With Glutamate Targeting Medications for the Treatment of Major Depressive DisorderGerard Sanacora
JAMA Psychiatry|February 20, 2020
Is This Where We Stand After Decades of Research to Develop More Personalized Treatments for Depression?Gerard Sanacora
Pageof 20

Showing results (1-10 of 195) with videos related to

Sort By:
Pageof 20
The American Journal of Psychiatry|March 2, 2019
Caution Against Overinterpreting Opiate Receptor Stimulation as Mediating Antidepressant Effects of KetamineGerard Sanacora
The Journal of Clinical Psychiatry|December 25, 2009
Do glutamatergic agents represent a new class of antidepressant drugs? Part 2Gerard Sanacora
Biological Psychiatry|February 18, 2010
Cortical inhibition, gamma-aminobutyric acid, and major depression: there is plenty of smoke but is there fire?Gerard Sanacora
The Journal of Clinical Psychiatry|February 19, 2009
Reviewing medications for bipolar disorder: understanding the mechanisms of actionGerard Sanacora
JAMA Psychiatry|July 13, 2017
Ketamine for the Treatment of Depression-ReplyGerard Sanacora
The Journal of Clinical Psychiatry|March 7, 2009
New understanding of mechanisms of action of bipolar medicationsGerard Sanacora
The Journal of Clinical Psychiatry|November 13, 2009
Do glutamatergic agents represent a new class of antidepressant drugs? Part 1Gerard Sanacora
Biological Psychiatry|June 23, 2018
Hopes and Skepticism for Unraveling the Unique Mechanisms of Ketamine's Rapid Onset Antidepressant Actions in Rodent ModelsGerard Sanacora
JAMA Psychiatry|June 16, 2016
What Are We Learning From Early-Phase Clinical Trials With Glutamate Targeting Medications for the Treatment of Major Depressive DisorderGerard Sanacora
JAMA Psychiatry|February 20, 2020
Is This Where We Stand After Decades of Research to Develop More Personalized Treatments for Depression?Gerard Sanacora
Pageof 20